Frontlight ResearchEarly access
WithdrawnPhase 2
Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis
Key facts
- Who runs it
- Stanford University
- Where
- Stanford, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Starts
- 1 Dec 2030
- Expected to end
- Dec 2030
- Type of study
- Interventional
- Treatments tested
- Ivermectin Pill
- Record updated
- 2 December 2024
- Why it stopped
- Limited clinical capacity
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Must have at least one lesion of atopic dermatitis (At least 1% Body surface Area)
- 18 years of age or older
- Must be willing to take oral ivermectin once weekly for 4 weeks and monitor over 8 weeks
- For women of child bearing potential, a negative urine pregnancy test
- Women of child bearing potential are expected to use an effective method of birth control while participating in the study and for 1 month after taking the last dose
- For male subjects with female partners of childbearing potential, agreement to use adequate contraception while participating in the study and for 1 month after taking the last dose
- Has signed and dated the current Institutional Review Board approved informed consent document
- Must be able to read and speak English fluently
Who cannot take part
- Has had known or previous hypersensitivity or allergic reactions to oral ivermectin before
- Taking any medication known to interact with ivermectin like Dasabuvir (theoretical) or warfarin (probable)
- Has an immunologic or infectious disease (e.g. hepatitis, tuberculosis, HIV or AIDS, lupus rheumatoid arthritis) which could place the subject at risk or interfere with the accuracy of the study results
- Has a history of hypersensitivity to any substance in investigational preparation
- Has other skin conditions that might interfere with Atopic Dermatitis diagnosis and/or evaluation (i.e. psoriasis current active viral, bacterial and fungal skin infections) as assessed by the Investigator
- Any other condition or factor the Investigator or their duly assigned representative believes may affect the ability of the subject to complete the study or the interpretation
- History of congestive heart failure; cardiac arrhythmias; or other findings of ventricular dysfunction
- History of current evidence of malabsorption or liver disease
- Has any clinically significant medical condition or laboratory abnormality that would, in the opinion of the Investigator, put the patient at undue risk or interfere with the interpretation of the study results
- Is age <18 years old
- Is currently participating or has participated in another interventional clinical study in the past 2 weeks
- Is planning a trip to a sunny climate, to use tanning booths or use other UV sources throughout the course of this study
- Is currently pregnant or breastfeeding
- Cannot read and speak English fluently
- Does not have at least 1% body surface area with lesional atopic dermatitis
Where in United States
- Stanford Hospital and ClinicsStanford, United States
About the trial
What the trial wants to find out
This pilot trial studies how well a novel oral therapeutic agent performs to treat patients with atopic dermatitis, particularly facial dermatitis.
The group in the trial
- Oral treatmentTreatment being tested
12mg oral ivermectin treatment taken once a week for four weeks
Treatment: Ivermectin Pill
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 2 December 2024